{
  "id": 9131813,
  "title": "Cantor Fitzgerald upgrades Omeros stock rating on Yartemlea launch",
  "url": "https://urgent.news/2026/09/22/cantor-fitzgerald-upgrades-omeros-stock-rating-on-yartemlea-launch",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-22T11:20:41.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-upgrades-omeros-stock-rating-on-yartemlea-launch-93CH-4910494"
  },
  "original_language": "en",
  "account": "Cantor Fitzgerald has raised its rating on Omeros stock following the successful launch of Yartemlea, a newly approved drug. The investment firm upgraded Omeros Corp. (NASDAQ:OMER) from a Neutral rating to Overweight and set a price target of $22.00 per share. Omeros' stock is currently trading at $18.49, close to its 52-week high of $19.65. The firm's upgrade is based on stronger-than-expected performance following the drug's launch and positive feedback from physicians. The assessment was made after reviewing the company's second-quarter results, which also surpassed Wall Street expectations. Omeros reported adjusted earnings of $0.02 per share, a significant improvement from the prior year's $0.25 loss per share. Revenue also exceeded forecasts, reaching $28.5 million compared to the expected $12.67 million. Omeros specializes in developing and commercializing pharmaceutical products and is based in Seattle.",
  "summary": null,
  "key_points": [
    "Cantor Fitzgerald upgraded Omeros stock rating to Overweight.",
    "Upgraded from Neutral rating with $22.00 price target per share.",
    "Omeros stock at $18.49, near 52-week high of $19.65."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Cantor Fitzgerald reiterates Neutral rating on Merck stock at $120",
        "url": "https://urgent.news/2026/09/22/cantor-fitzgerald-reiterates-neutral-rating-on-merck-stock-at-120",
        "published": "2026-09-22T12:30:50.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}